---
title: Treatment Duration of IPA
nct_id: NCT06583512
overall_status: ACTIVE_NOT_RECRUITING
sponsor: "Peking University People's Hospital"
study_type: OBSERVATIONAL
primary_condition: Invasive Aspergillosis
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06583512.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06583512"
ct_last_update_post_date: 2024-12-27
last_seen_at: "2026-05-12T06:29:42.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment Duration of IPA

**Official Title:** Invasive Pulmonary Aspergillosis Treatment Duration of Posaconazole-initiated Antifungal Strategy in Patients with Hematological Malignancies: a Prospective, Single-center Study

**NCT ID:** [NCT06583512](https://clinicaltrials.gov/study/NCT06583512)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 15
- **Lead Sponsor:** Peking University People's Hospital
- **Conditions:** Invasive Aspergillosis, Antifungal Therapy
- **Start Date:** 2024-12-01
- **Completion Date:** 2026-08-31
- **CT.gov Last Update:** 2024-12-27

## Brief Summary

The goal of this observational study is to identify the duration of posaconazole-initiated antifungal treatment for IPA in patients with hematological malignancies and to explore the value of monitoring immune factors and cells in IPA treatment in order to assess practices in IPA management in Chinese hematology patients including tools to evaluate duration and discontinuation. The main question it aims to answer is:

Does any indicators that could be used to guide the duration of IPA treatment? Does immune factors have value in monitoring IPA treatment? We will not do any interventions to participants. Participants will be monitored routinely for their clinical characteristics, microbiological test( including G/GM Test, Blood culture), Imaging examination, Blood routine, the number and function of immune cells, cytokines(IL-1β/IL-2/IL-4/IL-8/IL-10/IL-12/IL-17/IFN-α/IFN-γ/TNF-α)， and we will collect these datas for analysing.

## Detailed Description

1. A total of 15 patients will be involved in the study.
2. For each patient, the investigator will first evaluate the patient to determine if the patient meets the enrollment criteria and does not meet any of the exclusion criteria.
3. For the patients included in the study, the investigators will collect their blood RT, immune cell count and function, and cytokine levels (including IL-1β/IL-2/IL-4/IL-5/IL-6/IL-8/IL-10/IL-12/IL-17/INF-γ/INF-α/TNF-α et al).
4. Closely monitor the patient's status and discontinue antifungal therapy if the patient meet the 4 critera: ①PMNs recovery\>500；②previous signs/symptoms of active IPA (such as fever) has been resolved; ③nagative mycological evidence; ④CT: the reduction in the size of the lesion must exceed 90% or stable cave. If the patient does not meet any of these criteria, antifungal therapy is continued until the 4 critera are met.
5. Blood RT, neutrophil count and function, and cytokine levels (IL-1β/IL-2/IL-4/IL-5/IL-6/IL-8/IL-10/IL-12/IL-17/INF-γ/INF-α/TNF-α) were collected at the time of stopping antifungal therapy and at 2, 4, 8, and 12 weeks after stopping treatment. At the same time, the patient's symptoms (cough, hemoptysis, fever, etc. )and signs (chest pain, etc. ) were observed and the patient's microbiology examination results (blood G/GM text, fungal culture, etc. ) and imaging examination results (CT, etc.) were collected at the follow-up.
6. Follow-up will be conducted instantly if any symptom, sign, or text result suspected IPA after discontinuation.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Informed consent form signed
2. Patient with hematological malignancies
3. Patients with posaconazole-initiated antifungal therapy
4. Treatment duration ≥12w

Exclusion Criteria:

1. Refuse to enroll
2. Pregnancy or breastfeeding women
3. Are expected to survive no more than 72 h
4. Fungal or mycobacterial lung co infection at time of IPA diagnosis
5. Hematological malignancy with lung location
6. Disseminated aspergillosis (lung and sinus aspergillosis can be included)
```

## Primary Outcomes

- **The duration of posaconazole-initiated antifungal treatment therapy for IPA in patients with hematological malignancies** _(time frame: 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_ — The primary outcome is the duration of posaconazole-initiated antifungal treatment therapy for IPA in patients with hematological malignancies

## Secondary Outcomes

- **All-cause mortality on 2/4/8 /12 weeks after discontinuation** _(time frame: 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_
- **IFI-free survival rate on 2/4/8/12 weeks after discontinuation** _(time frame: 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_
- **Clinical success rate of posaconazole-initiated antifungal therapy** _(time frame: 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_
- **The proportion of patients who restarted treatment after discontinuation** _(time frame: 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_
- **Analysis of criteria that could be used to guide the discontinuation of IPA treatment** _(time frame: 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_
- **The value of immune factors (IL-1β/IL-2/IL-4/IL-5/IL-6/IL-8/IL-10/IL-12/IL-17/IFN-α/IFN-γ/TNF-α) and cells (the count of neutrophil and lymphocytes)** _(time frame: from the beginning of posaconazole-initiated treatment to 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_
- **The trend of immune factors (IL-1β/IL-2/IL-4/IL-5/IL-6/IL-8/IL-10/IL-12/IL-17/IFN-α/IFN-γ/TNF-α) and cells (the count of neutrophil and lymphocytes)** _(time frame: from the beginning of posaconazole-initiated treatment to 12 weeks after discontinuation of posaconazole-initiated antifungal therapy)_

## Locations (1)

- Peking University People's Hospital, Beijing, Beijing Municipality, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.peking university people's hospital|beijing|beijing municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06583512.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06583512*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*